| Cell line name |
YPK-2 |
|---|
| Accession |
CVCL_WK52 |
|---|
| Resource Identification Initiative |
To cite this cell line use: YPK-2 (RRID:CVCL_WK52) |
|---|
| Comments |
Population: Japanese. |
|---|
| HLA typing |
Source: PubMed=18575732
| Class I | | HLA-A | A*02,24 | | HLA-B | B*03,39 | | HLA-C | C*12 |
|
|---|
| Disease |
Pancreatic adenocarcinoma (NCIt: C8294) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Sex of cell |
Sex unspecified |
|---|
| Age at sampling |
Age unspecified |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=18575732; DOI=10.3892/or.20.1.155
Kawaoka T., Oka M., Takashima M., Ueno T., Yamamoto K., Yahara N., Yoshino S., Hazama S.
Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Oncol. Rep. 20:155-163(2008) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q98136397
|
|---|
| Entry history |
|---|
| Entry creation | 24-May-2019 |
|---|
| Last entry update | 21-Mar-2023 |
|---|
| Version number | 4 |
|---|
